Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease

Details for Australian Patent Application No. 2006284841 (hide)

Owner Schering Corporation The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services

Inventors Caspi, Rachel; Kastelein, Robert A.; Tsai, Van T.; Silver, Phyllis; Luger, Dror; Cua, Daniel J.

Agent Griffith Hack

Pub. Number AU-A-2006284841

PCT Pub. Number WO2007/027761

Priority 60/713,792 01.09.05 US; 60/837,312 11.08.06 US

Filing date 30 August 2006

Wipo publication date 8 March 2007

International Classifications

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 27/00 (2006.01) Drugs for disorders of the senses

Event Publications

3 April 2008 PCT application entered the National Phase

  PCT publication WO2007/027761 Priority application(s): WO2007/027761

4 October 2012 Alteration of Name

  The name of the applicant has been altered to The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services; Merck Sharp & Dohme Corp.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006284845-Multi-rotor wind turbine supported by continuous central driveshaft

2006284832-NMR device for detection of analytes involving magnetic particles